RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Fibrodysplasia Ossificans Progressiva: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Total Syntheses and Biological Evaluation of Lamellolactones A and B via Direct Butenolide Functionalization.
Fuse Yuto et al., The Journal of organic chemistry (20 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42896125/
- 2.
Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Papa Riccardo et al., Lancet (London, England) (17 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42805227/
- 3.
A novel and effective treatment for fibrodysplasia ossificans progressiva.
Schipani Ernestina, Lancet (London, England) (17 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42805228/
- 4.
Precision RNAi for fibrodysplasia ossificans progressiva in mice using a combinatorial unimolecular allele selective approach
Yeon-Suk Yang et al., Nature Communications (16 October 2026)
https://doi.org/10.1038/s41467-026-78738-9
- 5.
In-Silico Drug Repurposing Pipeline for Fibrodysplasia Ossificans Progressiva (FOP): ACVR1 Target Analysis with CuraNode
Santiago Maroto, Zenodo (CERN European Organization for Nuclear Research) (15 October 2026)
https://doi.org/10.5281/zenodo.23404203
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
NCT05394116 · Active (not recruiting) · Phase 3 · Regeneron Pharmaceuticals
Ages 18 and over
https://clinicaltrials.gov/study/NCT05394116
- 2.
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
NCT05090891 · Recruiting · Phase 2 · Incyte Corporation
Ages 2 to 99
https://clinicaltrials.gov/study/NCT05090891
- 3.
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.
NCT05027802 · Completed · Phase 3 · Ipsen
Ages 14 and over
https://clinicaltrials.gov/study/NCT05027802
- 4.
A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).
NCT05039515 · TERMINATED · Phase 2 · Clementia Pharmaceuticals Inc.
Ages 5 and over
https://clinicaltrials.gov/study/NCT05039515
- 5.
An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.
NCT03312634 · Completed · Phase 3 · Clementia Pharmaceuticals Inc.
Ages 4 and over
https://clinicaltrials.gov/study/NCT03312634
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Fibrodysplasia Ossificans Progressiva
Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic condition caused by ACVR1 mutations, causing muscles, tendons, and ligaments to progressively turn into bone. Any injury or surgery triggers new bone formation. Palovarotene, the first approved treatment, reduces the volume of new heterotopic bone.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Lamellolactones A and B are pseudoregioisomeric natural products bearing oxidized butenolide frameworks and have attracted interest in the context of fibrodysplasia ossificans progressiva (FOP). We achieved their first total syntheses via Ni-catalyzed reductive coupling of a common alkyl iodide with α- and β-bromobutenolides. A preliminary examination of alkyl electrophiles indicated that the coupling could be applied to simple primary and secondary alkyl iodides. The route also furnished analogues for comparison of γ-substitution effects on bone morphogenetic protein (BMP)-induced alkaline phosphatase inhibition and cytotoxicity.
Common Questions
What is Fibrodysplasia Ossificans Progressiva?
Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic condition caused by ACVR1 mutations, causing muscles, tendons, and ligaments to progressively turn into bone. Any injury or surgery triggers new bone formation. Palovarotene, the first approved treatment, reduces the volume of new heterotopic bone.
How many clinical trials are available for Fibrodysplasia Ossificans Progressiva?
RareWays currently indexes 14 clinical trials for Fibrodysplasia Ossificans Progressiva, of which 1 is actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Fibrodysplasia Ossificans Progressiva come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Fibrodysplasia Ossificans Progressiva.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.